UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.
FDA Rejects Eli Lilly’s Donanemab For Alzheimer’s Disease, Needs More Data
The FDA issued a complete response letter for the accelerated approval submission of Eli Lilly And Co’s (NYSE:LLY) donanemab for early symptomatic…